Vera Therapeutics, Inc. (VERA) 10-Year Financial Performance & Capital Metrics

VERA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.Show more

Revenue $0
EBITDA -$167M -63.8%
Net Income -$152M -58.5%
EPS (Diluted) -2.75 -22.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -44.83% +58.3%
ROIC -38.65% +55.9%
Debt/Equity 0.09 -82.1%
Interest Coverage -21.92 +18.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 93 (top 7%)

✗Weaknesses

✗Shares diluted 29.5% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-87.49%

EPS CAGR

10Y-

5Y-

3Y-

TTM-57.85%

ROCE

10Y Avg-120.34%

5Y Avg-89.05%

3Y Avg-73.79%

Latest-42.67%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	509K	251K	0	-846K	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-509K	-251K	0	846K	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	0.51%	1%	-	-1%	-
Operating Expenses+	11.7M	47.81M	34.4M	91.75M	102.01M	167.17M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	4.41M	3.89M	11.92M	21.91M	23.79M	41M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	7.29M	43.92M	22.48M	69.84M	78.22M	126.17M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-11.96M	-48.06M	-34.4M	-90.9M	-102.01M	-167.17M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-3.02%	0.28%	-1.64%	-0.12%	-0.64%
EBITDA+	-11.45M	-47.81M	-34.23M	-91.75M	-101.99M	-167.06M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-3.17%	0.28%	-1.68%	-0.11%	-0.64%
D&A (Non-Cash Add-back)	509K	251K	176K	-846K	21K	105K
EBIT	-11.8M	-53.25M	-32.59M	-88.06M	-92.2M	-144.52M
Net Interest Income+	108K	-158K	-5K	758K	4.19M	13.09M
Interest Income	159K	8K	15K	1.75M	7.98M	20.71M
Interest Expense	51K	166K	20K	992K	3.79M	7.63M
Other Income/Expense	108K	-5.35M	1.79M	1.85M	6.02M	15.02M
Pretax Income+	-11.85M	-53.41M	-32.61M	-89.06M	-95.99M	-152.15M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	1K	1K	1K	1K	1K	1K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-11.85M	-53.41M	-32.61M	-89.06M	-95.99M	-152.15M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-3.51%	0.39%	-1.73%	-0.08%	-0.59%
Net Income (Continuing)	-11.85M	-53.41M	-32.61M	-89.06M	-95.99M	-152.15M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-3.46	-14.40	-2.43	-3.35	-2.25	-2.75
EPS Growth %	-	-3.16%	0.83%	-0.38%	0.33%	-0.22%
EPS (Basic)	-3.46	-14.40	-2.43	-3.35	-2.25	-2.75
Diluted Shares Outstanding	3.42M	3.71M	13.44M	26.57M	42.71M	55.33M
Basic Shares Outstanding	3.42M	3.71M	13.44M	26.57M	42.71M	55.33M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.56M	54.26M	82.54M	125.7M	172.02M	651.22M
Cash & Short-Term Investments	3.19M	53.65M	79.67M	114.65M	160.72M	640.85M
Cash Only	3.19M	53.65M	79.67M	43.46M	45.68M	92.65M
Short-Term Investments	0	0	0	71.19M	115.03M	548.21M
Accounts Receivable	0	52K	0	0	0	3.77M
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	4K	442K	480K	719K	3.22M	913K
Total Non-Current Assets+	1.82M	293K	1.21M	5.74M	3.52M	4.46M
Property, Plant & Equipment	1.39M	0	0	5.22M	3.04M	4.33M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	867K	58K	11K	0
Other Non-Current Assets	422K	293K	344K	455K	471K	131K
Total Assets+	5.38M	54.55M	83.75M	131.44M	175.55M	655.68M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	9.14%	0.54%	0.57%	0.34%	2.74%
Total Current Liabilities+	1.06M	2.41M	7.69M	25.6M	22.3M	25.37M
Accounts Payable	342K	909K	1.39M	11.99M	11.12M	7.67M
Days Payables Outstanding	245.25	1.32K	-	-5.17K	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	220K	960K	377K	0	4.82M	0
Current Ratio	3.36x	22.55x	10.73x	4.91x	7.71x	25.67x
Quick Ratio	3.36x	22.55x	10.73x	4.91x	7.71x	25.67x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	40.87M	141.5M	6.47M	28.93M	51.56M	53.16M
Long-Term Debt	0	0	4.92M	24.81M	49.88M	50.69M
Capital Lease Obligations	10K	0	0	3.83M	1.4M	2.47M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	40.86M	141.5M	1.54M	286K	286K	0
Total Liabilities	41.93M	143.9M	14.16M	54.53M	73.86M	78.53M
Total Debt+	132K	2K	4.92M	31.29M	53.71M	54.64M
Net Debt	-3.06M	-53.65M	-74.75M	-12.17M	8.03M	-38.01M
Debt / Equity	-	-	0.07x	0.41x	0.53x	0.09x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-234.53x	-289.52x	-1720.10x	-91.64x	-26.94x	-21.92x
Total Equity+	-36.55M	-89.35M	69.59M	76.91M	101.69M	577.15M
Equity Growth %	-	-1.44%	1.78%	0.11%	0.32%	4.68%
Book Value per Share	-10.68	-24.10	5.18	2.89	2.38	10.43
Total Shareholders' Equity	-36.55M	-89.35M	69.59M	76.91M	101.69M	577.15M
Common Stock	0	0	21K	28K	44K	64K
Retained Earnings	-38.03M	-91.45M	-124.06M	-213.11M	-309.1M	-461.25M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	-224K	251K	393K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.29M	-34.81M	-23.71M	-67.6M	-92.18M	-134.68M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-2.38%	0.32%	-1.85%	-0.36%	-0.46%
Net Income	-11.85M	-53.41M	-32.61M	-89.06M	-95.99M	-152.15M
Depreciation & Amortization	509K	251K	176K	-846K	-4.09M	105K
Stock-Based Compensation	263K	331K	3.01M	8.89M	11.49M	20.8M
Deferred Taxes	0	0	-1.8M	0	0	0
Other Non-Cash Items	277K	17.9M	4M	6.67M	2.27M	-6.1M
Working Capital Changes	516K	123K	3.51M	6.75M	-5.87M	2.66M
Change in Receivables	159K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	-291K	567K	475K	10.61M	-873K	-3.45M
Cash from Investing+	-125K	-42K	-4.2M	-70.55M	-39.43M	-425.03M
Capital Expenditures	-125K	-99K	0	-62K	-63K	-972K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	57K	-5M	-70.49K	0	8.97M
Cash from Financing+	-137K	85.29M	53.88M	101.93M	133.54M	606.67M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	51K	-182K	-2.21M	-4.01M	-6.2M	-25.85M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-10.41M	-34.91M	-23.71M	-67.66M	-92.24M	-135.65M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-2.35%	0.32%	-1.85%	-0.36%	-0.47%
FCF per Share	-3.04	-9.41	-1.76	-2.55	-2.16	-2.45
FCF Conversion (FCF/Net Income)	0.87x	0.65x	0.73x	0.76x	0.96x	0.89x
Interest Paid	51K	32K	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-46.86%	-121.58%	-107.5%	-44.83%
Return on Invested Capital (ROIC)	-	-	-	-228.87%	-87.72%	-38.65%
Debt / Equity	-	-	0.07x	0.41x	0.53x	0.09x
Interest Coverage	-234.53x	-289.52x	-1720.10x	-91.64x	-26.94x	-21.92x
FCF Conversion	0.87x	0.65x	0.73x	0.76x	0.96x	0.89x

Frequently Asked Questions

Growth & Financials

Vera Therapeutics, Inc. (VERA) grew revenue by 0.0% over the past year. Growth has been modest.

Vera Therapeutics, Inc. (VERA) reported a net loss of $251.9M for fiscal year 2024.

Dividend & Returns

Vera Therapeutics, Inc. (VERA) has a return on equity (ROE) of -44.8%. Negative ROE indicates the company is unprofitable.

Vera Therapeutics, Inc. (VERA) had negative free cash flow of $211.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener